Literature DB >> 2840037

Cyclosporin A induced augmentation of the beta-adrenergic adenylate cyclase response of pig epidermis.

N Kato1, K M Halprin, J R Taylor, A Ohkawara.   

Abstract

It has been known that beta-adrenergic adenylate cyclase response is decreased in psoriatic-involved epidermis. Since the immunosuppressive agent, cyclosporin A, is reported to be effective on psoriasis clinically, the effect of cyclosporin A on beta-adrenergic adenylate cyclase response in pig skin was examined in vitro. Therapeutic serum levels of cyclosporin A (100-400 ng/ml) augmented the beta-adrenergic adenylate cyclase response of the epidermis. Highest levels of cyclosporin A (2-20 micrograms/ml) did not have any effect on its response. Both low Km and high Km cyclic AMP phosphodiesterases were not affected by cyclosporin A. Therefore, it is suggested that the clinical efficacy of cyclosporin A on psoriasis can be explained partially by its direct effect on the keratinocyte itself.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840037     DOI: 10.1007/BF00417710

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  25 in total

1.  Defective function of T lymphocytes in psoriasis.

Authors:  W Glinski; S Obałek; A Langner; S Jabłonska; M Haftek
Journal:  J Invest Dermatol       Date:  1978-02       Impact factor: 8.551

2.  Cyclosporin A and psoriasis.

Authors:  B E Monk
Journal:  Br J Dermatol       Date:  1986-08       Impact factor: 9.302

3.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

4.  Treatment of cutaneous T cell lymphoma with cyclosporin A.

Authors:  A A Moreland; D B Robertson; L T Heffner
Journal:  J Am Acad Dermatol       Date:  1985-05       Impact factor: 11.527

5.  Cyclosporin for psoriasis.

Authors:  J I Harper; A C Keat; R C Staughton
Journal:  Lancet       Date:  1984-10-27       Impact factor: 79.321

6.  Drug transforms transplant medicine.

Authors:  G Kolata
Journal:  Science       Date:  1983-07-01       Impact factor: 47.728

7.  On the lack of response to catecholamine stimulation by the adenyl cyclase system in psoriatic lesions.

Authors:  K Yoshikawa; K Adachi; K M Halprin; V Levine
Journal:  Br J Dermatol       Date:  1975-06       Impact factor: 9.302

8.  Glucocorticoid-induced modulation of the beta-adrenergic adenylate cyclase response of epidermis: its relation to epidermal phospholipase A2 activity.

Authors:  H Iizuka; S Kajita; T Mizumoto; H Kawaguchi
Journal:  J Invest Dermatol       Date:  1986-11       Impact factor: 8.551

9.  Dermatological aspects of the use of Cyclosporin A for prophylaxis of graft-versus-host disease.

Authors:  J I Harper; J R Kendra; S Desai; R C Staughton; A J Barrett; J R Hobbs
Journal:  Br J Dermatol       Date:  1984-04       Impact factor: 9.302

10.  Expression of HLA-DR antigen in skin from patients with psoriasis.

Authors:  V B Morhenn; E A Abel; G Mahrle
Journal:  J Invest Dermatol       Date:  1982-02       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.